This Diagnostics Devices Stock Rises 100% in 1 Year: What Is Driving the Rally?

This diagnostics devices stock has risen approximately 100% in one year, turning Rs 1 lakh into close to Rs 2 lakh before costs. The share closed at Rs 53.33 on 16 September 2025 and Rs 106.42 on 16 September 2026, a close to close gain of about 99.6%. That puts the diagnostics devices stock among the strongest performers on a screen of NSE small-cap stocks ranked by 1-year return, dated 16 September 2026.

The company is Morepen Laboratories Ltd, a diagnostics devices stock familiar to households through its Dr Morepen glucometers and blood pressure monitors. Morepen Labs also makes active pharmaceutical ingredients and formulations in Himachal Pradesh, and the Morepen Labs share price has spent 2026 climbing out of a deep hole. It bottomed at Rs 33.05 on 30 March 2026 and has more than tripled since.

Click Here – Get Free Investment Predictions

Diagnostics Devices Stock Returns Across Periods

The one year move is the headline, but the shape of the chart matters. Almost all of the gain in this diagnostics devices stock arrived after February 2026. Between September 2025 and late January 2026 the share actually fell, from about Rs 53 to Rs 33.98, as earnings weakened and small caps sold off.

The table below compares diagnostics devices stock returns across periods, close to close, using the nearest trading day where a date fell on a holiday.

Period	Price Return	Starting Reference Price
1 Month	Around +18%	Rs 89.82 on 17 August 2026
6 Months	Around +182%	Rs 37.75 on 16 March 2026
1 Year	Around +100%	Rs 53.33 on 16 September 2025
3 Years	Around +183%	Rs 37.60 on 15 September 2023
5 Years	Around +77%	Rs 60.20 on 17 September 2021

Over five years the diagnostics devices stock has compounded at roughly 12% a year, which is ordinary. Over six months it has been anything but. There was no split or bonus in the one year window, so the rise in the diagnostics devices stock is genuine price appreciation and not a corporate action artifact. Face value has stayed at Rs 2.

Why Did This Diagnostics Devices Stock Double in One Year?

Three things did the work: a large contract manufacturing mandate, a record June quarter, and a swing in export led profitability. The diagnostics devices stock was a laggard until one announcement in February 2026 reset how the market valued the business.

The Rs 825 Crore CDMO Mandate

On 23 February 2026 Morepen Labs announced a contract development and manufacturing mandate worth approximately Rs 825 crore from a global pharmaceutical company. The Morepen Labs share price jumped about 16% that session on volumes of roughly 119 million shares, the heaviest single day turnover this diagnostics devices stock had seen in years.

The size mattered because Morepen Labs reported FY26 revenue of Rs 1,827 crore. A multi-year mandate worth Rs 825 crore was a meaningful addition for a company growing slowly. Commercial supplies began around 1 July 2026, removing the execution doubt that usually trails such announcements and giving the diagnostics devices stock a second leg up.

A Record June 2026 Quarter

Results published on 4 August 2026 were the second catalyst for the diagnostics devices stock. Revenue for the June 2026 quarter came in at Rs 575.31 crore, up approximately 34% from Rs 429.65 crore a year earlier. EBITDA more than tripled to Rs 87.72 crore from Rs 28.58 crore, and net profit rose to Rs 56.35 crore from Rs 11.41 crore.

The operating margin expanded to 15.39% from 6.72%. The diagnostics devices stock hit a 20% upper circuit that day and made fresh highs through August. Around Rs 58 crore of dispatches under the new mandate landed inside the quarter, which told investors the contract was converting into cash.

Exports and API Market Share

Export revenue for the June quarter grew approximately 111% year on year. The active pharmaceutical ingredient business grew about 31%, with API exports up roughly 42%. Morepen Labs holds a large global share in a few molecules, including montelukast and loratadine, reported at around 70% and 69% respectively.

That concentration cuts both ways for the diagnostics devices stock. It gives pricing power in good years, and it exposes earnings to price erosion whenever a rival adds capacity in the same molecules.

The Devices Business as a Second Engine

The home healthcare and medical devices arm grew approximately 19% in the June quarter. This segment gives the diagnostics devices stock its identity with retail investors, covering glucose monitoring, blood pressure measurement and connected health products under the Dr Morepen brand. Management calls devices a second growth engine alongside contract manufacturing, and has outlined a phased capacity build targeting 1,200 KL by FY30.

Check the Univest Screener for Live Fundamentals of High-Return Stocks

Morepen Labs Financials: The Quarterly Trend

The quarterly numbers explain why the diagnostics devices stock spent the first half of the period going nowhere. Profitability was erratic through FY26 before the June 2026 jump.

Quarter	Revenue (Rs crore)	EBITDA (Rs crore)	Net Profit (Rs crore)	Operating Margin
Jun 2025	429.65	28.58	11.41	6.72%
Sep 2025	416.22	35.33	41.04	14.86%
Dec 2025	487.97	50.12	27.50	10.35%
Mar 2026	493.18	32.91	15.70	6.79%
Jun 2026	575.31	87.72	56.35	15.39%

For FY26, revenue was Rs 1,827.01 crore against Rs 1,829.94 crore in FY25, effectively flat, and net profit fell to Rs 95.65 crore from Rs 118.02 crore. So the diagnostics devices stock is being repriced on one strong quarter and a forward order book, not on a multi-year growth record. That distinction matters for anyone buying at current levels.

Valuation and Who Owns the Diagnostics Devices Stock

At Rs 106.42 the company carries a market capitalisation of approximately Rs 5,822 crore. The trailing PE of about 41 sits above the industry PE of roughly 38, so the diagnostics devices stock is no longer priced as a turnaround candidate.

Metric	Value
Market capitalisation	Around Rs 5,822 crore
PE ratio (trailing)	41.34
Industry PE	37.96
Price to book	4.67
Return on equity	5.96%
Debt to equity	0.17
Book value per share	Rs 22.75
Promoter holding (Jun 2026)	35.65%
FII holding (Jun 2026)	1.46%
DII holding (Jun 2026)	1.28%

Promoter holding has been steady at approximately 35.65% for five straight quarters. Institutional interest moved the other way. Foreign institutional holding slipped from about 2.22% in December 2024 to 1.46% in June 2026, and domestic institutional holding eased from around 1.64% to 1.28%. Roughly 61.6% of the diagnostics devices stock sits with public and non-institutional holders, which is part of why it moves so violently.

Risks In This Diagnostics Devices Stock

The first risk is arithmetic. A diagnostics devices stock that has doubled in a year and tripled in six months has already discounted a lot of good news. On 15 September 2026 the Morepen Labs share price fell approximately 8% in one session, from Rs 115.78 to Rs 106.22, and on 16 September it traded between Rs 97.09 and Rs 108.24. An intraday range above 11% is normal here, not exceptional.

Liquidity and volatility go together in this diagnostics devices stock. Daily volumes have swung from under a million shares in October 2025 to more than 119 million on event days. Thin sessions produce outsized moves in either direction, and a small cap of this size can gap down on one disappointing filing.

Returns on capital remain modest. Return on equity is approximately 5.96% and return on capital employed sits near 8%, both below what a price to book of 4.67 would normally justify. Cash generation is the related worry: FY26 operating cash flow was around Rs 32.64 crore against capital expenditure of roughly Rs 160.54 crore, so free cash flow was negative. Debt to equity has risen from about 0.03 in FY24 to 0.17, still low but moving one way.

Concentration is the fourth risk. Much of the excitement around the diagnostics devices stock rests on one mandate from one counterparty. Any delay, renegotiation or volume shortfall would hit sentiment hard, and the API book is similarly concentrated.

On the positive side, there is no promoter pledge disclosed in the latest filings, no insolvency or restructuring proceeding, and no recent renaming or merger. On publicly available exchange data at the time of writing, this diagnostics devices stock is not under additional surveillance measures, though small caps that move this fast can attract short term surveillance curbs at any point.

Download the Univest iOS App or Univest Android App to track the Morepen Labs share price live

Morepen Labs Share: Analyst View

Formal sell side coverage of Morepen Labs is thin, which is common at this size. Most available commentary is technical rather than fundamental, and the name does not feature in the regular research universe of larger institutional desks. Investors in this diagnostics devices stock are therefore working with less independent scrutiny than they would get on a larger company.

What can be said is that the market has moved from valuing Morepen Labs as a slow growing supplier to valuing it as a contract manufacturing partner with a devices franchise attached. Whether that re-rating holds depends on the September 2026 quarter. If revenue and margin hold near June levels, the multiple on this diagnostics devices stock is defensible. If the June quarter proves to be a one off aided by dispatch timing, it has a long way to fall.

Morepen Labs Share Price Target

No verified brokerage target is available for Morepen Labs at the time of writing, so any Morepen Labs share price target circulating on social media deserves caution. Without published research on this diagnostics devices stock, the sensible reference points are the traded levels themselves.

The 52 week high is Rs 122.55, made on 8 September 2026, and the 52 week low is Rs 33.05 from 30 March 2026. The Morepen Labs share price target question therefore reduces to two parts: can the diagnostics devices stock reclaim Rs 122.55 on the September quarter, and where is support if it cannot. The August consolidation zone between Rs 88 and Rs 96 is the nearest visible support, and the June 2026 base near Rs 50 is the deeper one. Anchor to those levels and to quarterly delivery rather than to round numbers.

Other Stocks to Track From the Same Return Screen

Beyond this diagnostics devices stock, a screen of NSE small-cap stocks ranked by 1-year return also includes related names such as Novartis India with a 1-year return of 126.70%, Senores Pharmaceuticals at 104.38% and Sigma Advanced Systems at 393.07%.

Among the names covered from that screen, MTAR Technologies returned 396.53% over one year. Readers can compare this diagnostics devices stock with the Nifty 50 benchmark and track each of these names on Univest before making any decision.

Conclusion

A 100% one year gain in this diagnostics devices stock is real, verified on close to close prices, and driven by identifiable events rather than rumour. The Rs 825 crore mandate, the record June quarter and the export surge are documented. The Morepen Labs share price reflects that, and then some.

What the price does not yet reflect is evidence that the June quarter is repeatable. Return on equity near 6%, negative free cash flow and flat full year revenue sit awkwardly beside a PE above 40. Anyone buying the diagnostics devices stock today is underwriting execution on one large contract and on a devices business that grew 19%. That is a reasonable bet with a small position and a clear exit plan, and an expensive one with conviction money. Consult a SEBI registered adviser before acting.

Frequently Asked Questions

Which diagnostics devices stock rose 100% in 1 year?

Ans. Morepen Laboratories Ltd (NSE: MOREPENLAB) is the diagnostics devices stock that gained approximately 100% over one year. The share moved from a close of Rs 53.33 on 16 September 2025 to Rs 106.42 on 16 September 2026, a verified close to close gain of about 99.6%.

Why did the Morepen Labs share price rise so sharply in 2026?

Ans. The rally in this diagnostics devices stock was triggered by a contract manufacturing mandate worth approximately Rs 825 crore announced on 23 February 2026, followed by record June 2026 quarter results on 4 August 2026. Net profit rose to Rs 56.35 crore from Rs 11.41 crore, and the share hit a 20% upper circuit.

What were Morepen Labs Q1 FY27 results?

Ans. Revenue for the June 2026 quarter was Rs 575.31 crore, up approximately 34% year on year. EBITDA rose to Rs 87.72 crore from Rs 28.58 crore, net profit came in at Rs 56.35 crore, and the operating margin expanded to 15.39% from 6.72%.

What is the 52 week high and low of Morepen Labs?

Ans. The 52 week high is Rs 122.55, touched on 8 September 2026, and the 52 week low is Rs 33.05 from 30 March 2026. The Morepen Labs share price was trading near Rs 106 on 16 September 2026, roughly 13% below its peak.

Is there a Morepen Labs share price target from brokerages?

Ans. No verified brokerage target is available for the company at the time of writing, because formal sell side coverage is limited. Investors discussing targets for this diagnostics devices stock usually reference the 52 week high of Rs 122.55 on the upside and the Rs 88 to Rs 96 consolidation band as near term support.

Was there any stock split or bonus issue in Morepen Labs during the year?

Ans. No. There was no stock split or bonus issue in the one year window, and the face value has remained at Rs 2. The gain in this diagnostics devices stock is genuine price appreciation rather than the result of a corporate action.

Is the diagnostics devices stock expensive at current levels?

Ans. The trailing PE of approximately 41 is above the industry PE of about 38, and price to book is 4.67 against a return on equity of only 5.96%. That combination means the diagnostics devices stock is pricing in future earnings rather than the current record.

What are the main risks in Morepen Labs shares?

Ans. The largest risks in this diagnostics devices stock are dependence on one large contract manufacturing mandate, concentration in a few API molecules, negative free cash flow in FY26 and high day to day volatility. Foreign and domestic institutional holdings have also been falling since December 2024.